Skip to main content

Table 1 Patient’s characteristics

From: Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma

Characteristic

n

(%)

Gender

  

  Male

54

75.0

  Female

18

25.0

Age (year)

  

  Median

60

 

  Range

21-80

 

ECOG PS

  

  0

23

31.9

  1

49

68.1

Hepatitis

  

  No

2

2.8

  Yes

70

97.2

    HBV

52

72.2

    HCV

6

8.3

    Others

12

16.7

Liver cirrhosis

  

  No

16

22.2

  Yes

56

77.8

PVTT

  

  No

30

41.7

  Yes

42

58.3

AFP (IU/mL)

  

  <400

48

66.7

  ≥400

24

33.3

Child-Pugh class

  

  A

54

75.0

  B

18

25.0

AJCC stage

  

  II

12

16.7

  III

53

73.6

  IVA

7

9.7

Previous treatment

  

  No

7

9.7

  Yes

65

90.3

    TACE

63

87.5

    RFA

7

9.7

    PEI

7

9.7

    Surgery

9

12.5

Treatment after RT

  

  No

31

43.1

  Yes

41

56.9

    TACE

40

55.6

    RFA

2

2.8

    PEI

2

2.8

    Systemic CTx

3

4.2

Radiation dose

  

  40 Gy/10 fxs

6

8.3

  45 Gy/10 fxs

10

13.9

  50 Gy/10 fxs

56

77.8

  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status; HBV hepatitis B virus; HCV hepatitis C virus; PVTT portal vein tumor thrombosis; AFP alpha-fetoprotein; AJCC American Joint Committee on Cancer; TACE transcatheter arterial chemoembolization; RFA radiofrequency ablation; PEI percutaneous ethanol injection; RT radiotherapy; CTx chemotherapy; fxs fractions.